A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD)
Latest Information Update: 13 Feb 2025
Price :
$35 *
At a glance
- Drugs Antithymocyte globulin (Primary) ; Cyclophosphamide (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 30 Aug 2021 Planned primary completion date changed from 30 Jun 2021 to 13 Oct 2024.
- 03 Mar 2021 Status changed from not yet recruiting to recruiting.
- 20 Dec 2019 New trial record